By inhibiting the activities of PKM2 and Cat, it is expected to break the abnormal metabolic patterns and immune escape mechanisms of tumor cells, opening up new avenues for the treatment of cancer and related metabolic diseases, the current clinical studies related to PKM2 and Cat are shown in (Table 2) below. This evidence concerns the gene CAT and neoplasm.